Tarsons Products Limited — PPTs, 11-08-2026: Investor Presentation

Tarsons Products showed robust performance in Q1 FY27! Consolidated revenue climbed 21% YoY to ₹110.2 Cr, driven by strong domestic business growth of 17% and a significant 29% surge in exports. While consolidated EBITDA rose 5% to ₹26.0 Cr, profitability was impacted. PAT turned negative at -₹1.4 Cr, mainly due to higher raw material prices from supply chain issues and initial expenses related to new manufacturing facilities. However, Cash PAT demonstrated resilience, growing 18% to ₹25.6 Cr.

The company's strategic focus involves expanding its product portfolio, particularly in the promising cell culture segment, and enhancing capacity with new state-of-the-art facilities at Panchla and Amta. These investments are crucial for onboarding new customers and scaling the export business, reinforcing its competitive positioning.

The Amta facility has already commenced commercial supplies, and the specialized cell culture lines at the Panchla facility are expected to be fully operational by the end of Q2 FY27. Management is optimistic about sustained demand momentum and anticipates margin recovery as utilization rates improve at these new facilities over the next two years. Tarsons is clearly investing in its long-term growth trajectory.